Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
Running, not enrolling · Phase 2
Conditions studied: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
In brief
This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see whether study participants remain MRD-negative after they stop treatment with venetoclax.
Key facts
- Study ID
- NCT04419519
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 81
- Starts
- 2020-05-13
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-07-10
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan Kettering Basking Ridge (All protocol activities) — Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (All protocol activities) — Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (All protocol activities) — Montvale, New Jersey, United States
- Memorial Sloan Kettering Commack (All protocol activities) — Commack, New York, United States
- Memorial Sloan Kettering Westchester (All protocol activities) — Harrison, New York, United States
- Columbia University — New York, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York, New York, United States
- Memorial Sloan Kettering Nassau (All protocol activities) — Uniondale, New York, United States
- University of Washington — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.